Organization | Fundacion SEIMC-GESIDA

Fundacion SEIMC-GESIDA Report issue

Foundation Phase 2 Phase 4

Founded: Madrid Spain (2008)

Organization Overview

First Clinical Trial

2008

NCT00866021

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Fundacion SEIMC-GESIDA

Active Ingredients

Drugs in Phase 4 Trials (20)

abacavir (ziagen) (4 trials)

amphotericin b (fungizone) (1 trial)

anidulafungin (eraxis) (1 trial)

atazanavir (reyataz) (1 trial)

bictegravir (Biktarvy) (4 trials)

cobicistat (stribild) (2 trials)

darunavir (prezista) (2 trials)

dolutegravir (tivicay) (6 trials)

elvitegravir (vitekta) (1 trial)

emtricitabine (emtriva) (7 trials)

fosamprenavir (lexiva) (1 trial)

human papillomavirus 9-valent vaccine, recombinant (Gardasil 9) (1 trial)

lamivudine (epivir) (10 trials)

lopinavir (Kaletra) (3 trials)

ribavirin (virazole) (1 trial)

ritonavir (Norvir) (4 trials)

sofosbuvir (sovaldi) (1 trial)

tenofovir (viread) (2 trials)

tenofovir alafenamide (genvoya) (6 trials)

zidovudine (retrovir) (1 trial)

Drugs in Phase 2 Trials (1)

tocilizumab (actemra) (1 trial)

Drugs in Other Trials (1)

cidofovir (vistide) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acquired Immunodeficiency Syndrome (Phase 4)

Coinfection (Phase 4)

Communicable Diseases (Phase 4)

Hepatitis C (Phase 4)

Hepatitis C, Chronic (Phase 4)

HIV Infections (Phase 4)

Infections (Phase 4)

Inflammation (Phase 4)

Lipodystrophy (Phase 4)

Liver Diseases (Phase 4)

Mycoses (Phase 4)

Neurotoxicity Syndromes (Phase 4)

Pneumonia (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 19
# of Trial APIs: 22